Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by increased mortality associated with cardiometabolic disorders including dyslipidaemia, insulin resistance, and cachectic obesity. Tumour necrosis factor inhibitors and interleukin 6 receptor blocker licensed for the treatment of RA decrease inflammation and could thus improve cardiovascular risk, but their effects on body composition and metabolic profile need to be clarified. We investigated the effects of tocilizumab (TCZ), a humanized anti‐interleukin 6 receptor antibody, on body composition and metabolic profile in patients treated for RA. Methods: Twenty‐one active RA patients treated with TCZ were included in a 1 year open follow‐up study. Waist circumference, body mass index, blood pressure, lipid profile, fasting glucose, insulin, serum levels of adipokines and pancreatic/gastrointestinal hormones, and body composition (dual‐energy X‐ray absorptiometry) were measured at baseline and 6 and 12 months of treatment. At baseline, RA patients were compared with 21 non‐RA controls matched for age, sex, body mass index, and metabolic syndrome. Results: Compared with controls, body composition was altered in RA with a decrease in total and appendicular lean mass, whereas fat composition was not modified. Among RA patients, 28.6% had a skeletal muscle mass index below the cut‐off point for sarcopaenia (4.8% of controls). After 1 year of treatment with TCZ, there was a significant weight gain without changes for fat mass. In contrast, an increase in lean mass was observed with a significant gain in appendicular lean mass and skeletal muscle mass index between 6 and 12 months. Distribution of the fat was modified with a decrease in trunk/peripheral fat ratio and an increase in subcutaneous adipose tissue. No changes for waist circumference, blood pressure, fasting glucose, and atherogenic index were observed. Conclusions: Despite weight gain during treatment with TCZ, no increase in fat but a modification in fat distribution was observed. In contrast, muscle gain suggests that blocking IL‐6 might be efficient in treating sarcopaenia associated with RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., Martin, F. C., Michel, J.-P., Rolland, Y., Schneider, S. M., et al. (2010) · Age and Ageing · doi:10.1093/ageing/afq034 · Cited by 11,601 · cited 1×
“Sarcopaenia is defined by both low muscle mass and muscle function (strength or performance) with a risk of physical disability, poor quality of life, and death.(5,6) During ageing and chronic diseases, decrease in lean mass is frequently associated with preserved or even increased body fat, notably ectopic fat in the…”
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
No adjustments are needed for multiple comparisons.
Rothman, K. J. (1990) · Epidemiology · doi:10.1097/00001648-199001000-00010 · Cited by 5,965
Do multiple outcome measures require p-value adjustment?
Feise, R. J. (2002) · BMC Medical Research Methodology · doi:10.1186/1471-2288-2-8 · Cited by 1,299 · cited 1×
“A particular focus was given to the magnitude of difference and to the clinical relevance.(23)”
Body Composition in Healthy Aging
BAUMGARTNER, R. N. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06498.x · Cited by 1,078 · cited 1×
“obesity defined on DXA by the association of an SMI below the gender-specific cut point for sarcopaenia and a body fat percentage above 27% for men and 38% for women.(24) In”
Osteosarcopenic obesity: the role of bone, muscle, and fat on health
Ormsbee, M. J., Prado, C. M., Ilich, J. Z., Purcell, S., Siervo, M., Folsom, A., & Panton, L. (2014) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-014-0146-x · Cited by 257 · cited 1×
“In turn, altered body composition is likely to impact health and causes a cascade of cardiometabolic abnormalities.(32,33)”
Insulin resistance and impaired beta cell function in rheumatoid arthritis
Dessein, P. H., & Joffe, B. I. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22053 · Cited by 218
Cited by
Tournadre, A., Vial, G., Capel, F., Soubrier, M., & Boirie, Y. (2019) · Joint Bone Spine · doi:10.1016/j.jbspin.2018.08.001 · Cited by 375
Self-citationC-reactive protein and implications in rheumatoid arthritis and associated comorbidities
Pope, J. E., & Choy, E. H. (2021) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.11.005 · Cited by 320
Interleukin 6 as an Energy Allocator in Muscle Tissue
Kistner, T. M., Pedersen, B. K., & Lieberman, D. E. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00538-4 · Cited by 295
Metadata
- Authors
- Tournadre, A., Pereira, B., Dutheil, F., Giraud, C., Courteix, D., Sapin, V., Frayssac, T., Mathieu, S., Malochet‐Guinamand, S., & Soubrier, M.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2017-03-18
- Volume
- 8
- Issue
- 4
- Pages
- 639-646
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W2597303623
- Cited by
- 185
- References
- 7
- FWCI
- 11.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. https://app.cochat.ai/papers/10.1002/jcsm.12189
- The paper
- Tournadre, A., Pereira, B., Dutheil, F., Giraud, C., Courteix, D., Sapin, V., Frayssac, T., Mathieu, S., Malochet‐Guinamand, S., & Soubrier, M. (2017). Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.12189
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.